孟鲁司特钠联合布地奈德治疗支气管哮喘临床疗效分析

Analysis of Clinical Efficacy of Montelukast Sodium Combined with Budesonide in the Treatment of Bronchial Asthma

目的评估孟鲁司特钠+布地奈德用药治疗方式实施在支气管哮喘患者中的情况。方法该文中对2018年4月—2020年1月该医院诊治的64例支气管哮喘患者开展项目有关指标统计,所采取分组方式选用抛硬币方式,每组32例,试验组选用传统治疗+孟鲁司特钠+布地奈德用药治疗方式,参照组选用传统治疗+布地奈德用药治疗方式,记录临床用药有效合计数值、咳嗽表现消除不见所用时长、喘息表现消除不见所用时长、哮鸣音表现消除不见所用时长、临床用药导致不良反应合计数值,评估临床用药之前和临床用药14 d之后最大呼气第1秒所呼出气量容积数据值、用力肺活量数据值。结果试验组临床用药有效(96.88%)较参照组(75.00%)上升,差异有统计学意义(χ^(2)=6.335,P<0.05);试验组咳嗽表现消除不见所用时长、喘息表现消除不见所用时长、哮鸣音表现消除不见所用时长(5.05±0.30)d、(3.40±0.12)d、(3.73±0.20)d对比参照组(7.10±0.56)d、(4.61±0.30)d、(5.60±0.48)d下降,差异有统计学意义(t=18.253、21.184、20.342,P<0.05);试验组临床用药导致不良反应(3.13%)对比参照组(18.75%)下降,差异有统计学意义(χ^(2)=4.010,P<0.05);试验组临床用药14 d之后最大呼气第1秒所呼出气量容积数据值、用力肺活量数据值(2.70±0.34)L、(3.23±0.40)L对比参照组(2.02±0.20)L、(2.60±0.31)L上升,差异有统计学意义(t=9.751、7.042,P<0.05)。结论为支气管哮喘患者选取孟鲁司特钠+布地奈德用药治疗方式得到较好给药效果。

Objective To evaluate the implementation of montelukast sodium+budesonide treatment in patients with bronchial asthma.Methods In this article,64 cases of bronchial asthma patients diagnosed and treated in the hospital from April 2018 to January 2020 were used to carry out project-related index statistics.The grouping method used was a coin toss method,with 32 cases in each group,and the experimental group used traditional treatment+montelus Special sodium+budesonide medication treatment mode,the reference group chooses traditional treatment+budesonide medication treatment mode,and records the effective total value of clinical medication,the length of time it takes for the cough to disappear,the time it takes for the wheeze to disappear,and the wheeze to disappear.The length of time used,the total number of adverse reactions caused by clinical medication,and the data value of expiratory volume and forced vital capacity in the first second of maximum expiration before clinical medication and 14 days after clinical medication.Results The clinical medication effect of the experimental group(96.88%)was higher than that of the reference group,the difference was statistically significant(75.00%)(χ^(2)=6.335,P<0.05);In the experimental group,the time it took to eliminate cough,wheeze and wheeze were(5.05±0.30)d,(3.40±0.12)d,(3.73±0.20)d,compared with the reference group(7.10±0.56)d,(4.61±0.30)d,(5.60±0.48)d decreased,the difference was statistically significant(t=18.253,21.184,20.342,P<0.05).Clinical medication in the experimental group caused a decrease in adverse reactions(3.13%),compared with the reference group(18.75%),the difference was statistically significant(χ^(2)=4.010,P<0.05);the maximum expiration in the experimental group after 14 days of clinical medication was the first second expiratory volume data value,forced vital capacity data value(2.70±0.34)L,(3.23±0.40)L compared to the reference group(2.02±0.20)L,(2.60±0.31)L increased,the difference was statistically significant(t=9.751,7.042,P<0.05).Conclusion Montelukast sodium+budesonide is selected for the treatment of patients with bronchial asthma to get a better drug effect.